Alebund Pharmaceuticals (Jiangsu) Limited (HKG:9637)

Hong Kong · Delayed Price · Currency is HKD

28.58

+1.92 (7.20%)

At close: Oct 7, 2026

Market Cap	9.71B
Revenue (ttm)	141.54M +368.3%
Net Income	-812.52M
EPS	-2.98
Shares Out	339.85M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	533,470
Open	26.68
Previous Close	26.66
Day's Range	25.68 - 29.00
52-Week Range	22.48 - 46.82
Beta	n/a
Analysts	Strong Buy
Price Target	48.49 (+69.66%)
Est. Earnings	Nov 26, 2026

About HKG:9637

Alebund Pharmaceuticals (Jiangsu) Limited operates as a biopharmaceutical company that develops therapies for kidney diseases and their complications in China and Hong Kong. Its products include AP301, a phosphate binder; AP306, a sodium-dependent phosphate transport protein inhibitor; one early-clinical-stage product candidate AP303; and four preclinical product candidates, including AP308, AP304, AP305, and AP307. Alebund Pharmaceuticals (Jiangsu) Limited was founded in 2018 and is headquartered in Yangzhou, China. [Read more]

Industry Drug Manufacturers - General

Sector Healthcare

Founded 2018

Employees 169

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 9637

Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

Analyst Summary

According to 3 analysts, the average rating for 9637 stock is "Strong Buy." The 12-month stock price target is $48.49, which is an increase of 69.66% from the latest price.

Price Target

$48.49

(69.66% upside)

Analyst Consensus: Strong Buy

Stock Forecasts